An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma

CD70 is expressed in up to 80% of nasopharyngeal carcinoma (NPC) cases. Cusatuzumab is a humanized anti‐CD70 monoclonal antibody, with dual action mechanisms: induction of cytotoxicity against CD70(+) tumor cells and reduction in CD70‐CD27 signaling mediated immune evasion. The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: De Meulenaere, Astrid, Vermassen, Tijl, Creytens, David, De Keukeleire, Stijn, Delahaye, Tim, Deron, Philippe, Duprez, Fréderic, Fung, Samson, Pauwels, Patrick, Ferdinande, Liesbeth, Rottey, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604223/
https://www.ncbi.nlm.nih.gov/pubmed/34405542
http://dx.doi.org/10.1111/cts.13089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604223/
https://www.ncbi.nlm.nih.gov/pubmed/34405542
http://dx.doi.org/10.1111/cts.13089

Ejemplares similares